NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Confluence Pharmaceuticals

Confluence Pharmaceuticals

Private
Arcadia, IndianaHealthcare & Life Scienceshttp://www.confluencepharma.com/

Last Round

Debt

Jun 21, 2022

Total Funding Raised

$2.1M

Company Overview

Confluence Pharmaceuticals is a biotechnology company developing novel therapeutic treatments for social and communication impairments caused by Fragile X Syndrome and Autism Spectrum Disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoveryclinical trialsFragile X Syndromeautism spectrum disordersorphan drugcontract research organizationCROtherapeutic developmentbiotechintellectual property licensingrare disease treatmentneurological disordersdrug pipelinepharma partnering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Confluence Pharmaceuticals Comparables

Compare Confluence Pharmaceuticals with similar companies based on industry and business-model similarity.

Confluence Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Yamo Pharmaceuticals
86%
Kaerus Bioscience
84%
PaxMedica, Inc.
83%

Confluence Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJun 21, 2022
VC RoundJun 17, 2021
DebtDec 2, 2020
VC RoundDec 20, 2018
Series A ExtensionSep 20, 2016

Confluence Pharmaceuticals Investors

Notable investors and investment history

Confluence Pharmaceuticals investors
InvestorRounds
Elevate VenturesSeries A Extension
IU VenturesDebt, VC Round
IU Philanthropic Venture FundDebt, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 20, 2016

    $1.3M round with Elevate Ventures and 21st-century-research-and-technology-fund.

Confluence Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Confluence Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Confluence Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersArcadia, Indiana
Employee Range3
Year Founded2010
Last FundingJun 21, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.